Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes ...
Earlier this month, Genentech offered countless academics and other researchers up to $125,000 in grants to generate papers ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the United States (U.S.) Food and Drug Administration (FDA) has accepted the company’s New Drug Application ...
The National Multiple Sclerosis Society today announced early progress in increasing access to comprehensive, quality care in ...
Genentech recently announced a series of marketing leadership hires to start off the new year. The biotech company hired Erica Taylor, PhD, as the company’s first chief marketing officer and tabbed ...
May 15, 2026, 1:58 PM ESTHealth Care May 06, 2026, 2:10 PM ESTHealth Care March 24, 2026, 4:10 PM ESTHealth Care April 08, 2026, 7:29 PM ESTCareer & Workplace March 02, 2026, 5:35 PM ESTHealth Care ...
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
Biotechnology company Genentech is expanding its local manufacturing capabilities with a $450 million investment in its Oceanside campus. Genentech was founded in 1976 and has been considered a ...
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
A rendering of the new biotech facility in Oceanside. Courtesy of Genentech Genentech has begun a $450 million expansion of its biotech campus in Oceanside with a new facility that will produce ...
InvestorsHub on MSN
Genentech highlights new breast cancer and precision oncology data ahead of ASCO 2026 (RHHBY)
Roche’s Genentech unit is emphasizing next-generation breast cancer therapies, targeted oncology combinations and brain-penetrating treatments at ASCO 2026. Key Investor Takeaways ・Genentech, part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results